Elixxer Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Karim Mecklai
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 100 Boulevard Rene- Levesque Ouest Montreal QC Canada H5B 4N4
- IPO Date
- Dec 14, 2017
- Website
- elixxer.com
- Similar Companies
- Business
- Elixxer Ltd. is a Canada-based investment company focused on the legal global cannabis market, with investments in pharmaceuticals and nutraceuticals, cultivation, production, and sale of cannabis and cannabis-derived products, as well as beauty and makeup-related opportunities. The company maintains stakes in licensed operators across Canada, Europe, and Jamaica, including a 19.36% equity position in Freia Farmaceutici Srl, an Italian firm specializing in hemp-based pharmaceutical products. Founded in 2004 and headquartered at 1100 Boulevard Rene-Levesque Ouest, Suite 700, Montreal, Quebec, Elixxer trades on the TSX Venture Exchange under ELXR and OTC Pink under ELIXF. Elixxer actively pursues high-growth opportunities beyond startups in the health and wellness sectors, emphasizing jurisdictions permitting legal cannabis activities. In recent developments, the company restructured significant debt obligations by extending $8 million in secured notes plus $3.8 million in accrued interest to September 30, 2025, and secured a $1 million bridge loan facility from AIP Fund, its largest creditor and 32% shareholder. It also proposed multiple debt-for-equity settlements, including $6.92 million via approximately 83.9 million shares at $0.0825 each subject to shareholder approval, and earlier amendments issuing over 470 million shares to AIP and Arlington Capital to settle portions of $7.3 million in debts each, positioning both as control persons with stakes around 34-40%; cease trade orders were revoked to resume trading, while new leadership including CEO Karim Mecklai and CFO Fiona Fitzmaurice was appointed in late 2024.
Elixxer Announces Adoption of Semi-Annual Reporting
Elixxer Provides Update on Secured and Unsecured Loans
Elixxer Announces Completion of Debt Settlement
Elixxer Announces Results of Annual and Special Meeting of Shareholders
Elixxer Ltd. Provides Update and Corrective Statements on Proposed Debt Settlement and Upcoming Shareholder Meeting
Elixxer Ltd. Announces Debt Settlement
Elixxer Ltd. Announces Proposed Shares for Debt Settlements
Elixxer Provides Corporate Update
Elixxer Announces Bridge Loan
Elixxer Ltd.: Revocation of Cease Trade Order
Elixxer Announces Results of Annual and Special Meeting of Shareholders
Elixxer Announces Appointment of Edward Milewski as a Director
Elixxer Announces Appointment of Mark Romano as a Director
Elixxer Announces Appointment of Fiona Fitzmaurice as Chief Financial Officer
Elixxer Announces Appointment of Karim Mecklai as Chief Executive Officer
Elixxer Announces Intention to Consolidate its Common Shares
Elixxer Announces Approval of Share Buyback
Elixxer's Largest Holding, Little Green Pharma, Completes Transformational Quarter
Elixxer Announces Intention to Make Normal Course Issuer Bid
Elixxer Ltd. Announces Amendment to Proposed Debt Settlement Transactions